🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInsurance & AccessPharmaceutical patient assistance programs — May 2025

Pharmaceutical patient assistance programs — May 2025

SarahChen_PharmD Wed, Jul 2, 2025 at 10:41 AM 23 replies 1,693 viewsPage 1 of 5
This thread is more than 11 months old. Information may be outdated. Consider searching for more recent discussions.
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Jul 2, 2025 at 10:41 AM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

Denials are usually procedural rather than clinical, and the order that works reflects that. Get the denial reason in writing, because it names the criterion you failed. Then supply the documentation that criterion asks for — usually documented BMI with a comorbidity, or a failed prior therapy. Then appeal, and ask for a peer-to-peer review, because a prescriber talking to a reviewing clinician resolves a large fraction of denials that written appeals do not. Manufacturer copay assistance is separate and applies mainly to commercial insurance, and patient assistance programmes are means-tested rather than a discount.

Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.

What I am trying to establish is what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
24 19Dr.ObesityLA, NurseKim_ATL, paul_denver and 21 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Jul 2, 2025 at 10:55 AM#2
SarahChen_PharmD said:
Denials are usually procedural rather than clinical, and the order that works reflects that.
SarahChen_PharmD said:
...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

  1. Document medical necessity (BMI, comorbidities, failed alternatives)
  2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
  3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
  4. Request peer-to-peer review between your doctor and the plan's medical director
  5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

Last edited: Jul 2, 2025 at 12:55 PM
23 18PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 20 others
Reply Quote Save Share Report
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
Jul 2, 2025 at 11:09 AM#3
SarahChen_PharmD said:
Denials are usually procedural rather than clinical, and the order that works reflects that.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.

22 17DadBodDave, AmyNC_wife, SkepticalSean and 19 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.EndoIndy
Member
267
1,234
Oct 2024
Indianapolis, IN
Jul 2, 2025 at 11:23 AM#4
RetaRick_CA said:
The affordability discussion here usually stops at individual tactics.

Financial impact of cost and coverage weight loss beyond medication cost:

  • Groceries: SAVED $206/month (eating less)
  • Restaurants: SAVED $156/month (fewer meals out)
  • Alcohol: SAVED $106/month (stopped drinking)
  • Life insurance: Premium REDUCED by $36/month (lower BMI)
  • Copays: SAVED $56/month (fewer BP/cholesterol meds)

Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.

21 16DeniseRN_TPA, SandraNC_45, Dr.EndoIndy and 18 others
Reply Quote Save Share Report
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
Jul 2, 2025 at 12:40 PM#5
Dr.MetabolicMD said:
SarahChen_PharmD said: ...my insurance denied cost and coverage coverage because...

Same experience, arrived at from the opposite direction.

20 15mike_mealprep, NicoleRaleigh, james_edin and 17 others
Reply Quote Save Share Report
1235

Similar Threads

Prior authorization success: step-by-step guide with templates5 replies
Cigna now covering Zepbound — how I got approved13 replies
Appeal letter template — denied PA for GLP-1 medications4 replies
Mounjaro savings card — manufacturer program changes 202610 replies
Medicare Part D GLP-1 coverage — what's covered in 202610 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register